Introduction
Galectin-1 (Gal1) is a member of a highly conserved family of carbohydrate-binding proteins that modulate innate and adaptive immune responses and foster tumor immune escape. [1] [2] [3] [4] Through the selective recognition of specific cell surface glycans (Gal-β1-4-NAcGlc [N-acetyllactosamine] units on the branches of N-or O-linked glycans) on receptors such as CD45, CD43 and CD7, Gal1 induces the apoptosis of specific T cell subtypes-Th1, Th17 and cytotoxic T cells. 5 Th2 cells have different patterns of sialylation of cell surface glycoproteins, lack Gal1 ligands, and resist Gal1-induced cell death. 5 Gal1 also instructs dendritic cells to become tolerogenic further limiting the magnitude of an effective immune response. 6 Primary classical Hodgkin lymphomas (cHLs) include small numbers of malignant ReedSternberg (RS) cells within a Th2-and T reg -cell skewed inflammatory infiltrate. In previous studies, we found that RS cells selectively overexpress Gal1 which promotes the immunosuppressive Th2/T reg predominant microenvironment in cHL. 4 Hodgkin RS cells exhibit constitutive AP-1 activation and express high levels of the AP-1 components, cJun and JunB. 7 In cHLs, the overexpression of Gal1 is driven, in large part, by an AP-1 dependent enhancer. 4 A significant percentage of cHLs are associated with Epstein-Barr virus (EBV) infection.
EBV is a B-lymphotropic γ herpes virus that infects over 90% of healthy individuals. [8] [9] [10] [11] After a primary infection and an associated brisk immune response, EBV persists in a latent state characterized by the limited expression of certain EBV antigens. 8 In immunocompetent patients, latent EBV infection and periodic viral reactivation are controlled by a vigorous virus-specific host T-cell response. 8, 10 However, patients who receive immunosuppressive therapy in association with hematopoietic stem cell or solid organ transplantation can reactivate the EBV type III latency (growth) program in infected B cells and develop post-transplantation lymphoproliferative disease (PTLD). 8 The latency type III (growth) program in EBV + PTLDs includes expression of the EBV nuclear antigens (EBNA-1, -2, -3A, -3C, and -LP), EBV-encoded RNAs (EBER-1 and -2) and the latent membrane proteins (LMP-1 and -2A). 8, 11 The LMP1 and LMP2A antigens promote B-cell transformation by mimicking the CD40 and B-cell antigen receptors,
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From respectively, 11, 12 and activating multiple signaling pathways, 13, 14 including AP-1, NFκB and PI3K/Akt. 11 PTLDs are a heterogeneous group of B-cell disorders that range from polyclonal B-cell hyperplasia to monoclonal aggressive B-cell lymphoma. 8, 10 Of interest, previous studies suggest that PTLDs also exist within a Th2-predominant microenvironment. 15 Current treatment options for PTLD include enhancing the underlying EBV-CTL response by reducing or withdrawing immunosuppression; however, this approach increases the risk of graft rejection and graft-vs-host disease. An alternative investigative approach is to generate and infuse EBV-specific donor cytotoxic T-cells (CTLs) directed against donor EBV-transformed lymphoblastoid B cell lines (LCLs) that present same viral antigens as the PTLD. 8, 16 Additional therapeutic strategies that augment endogenous or infusionassociated EBV specific T-cell immune responses are needed.
The postulated role of Gal1 in viral infections, [17] [18] [19] the link between Gal1 overexpression and tumor immune escape in cHL 4 and the shared characteristics of cHL and EBV-
driven PTLDs prompted us to analyze the role of Gal1 expression and function in EBVassociated PTLDs. Herein, we show that EBV-transformed LCLs and primary PTLDs overexpress Gal1 in a LMP2A-and LMP1-dependent manner. Furthermore, we report the development of a potent and highly specific neutralizing Gal1 monoclonal antibody (mAb) that inhibits Gal1-mediated apoptosis of EBV-specific CD8 + T cells. These data suggest that antibody-mediated Gal1 neutralization may represent a novel immunotherapeutic strategy for PTLD and other Gal1-expressing tumors.
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Materials and Methods
Cell lines. The L428 cHL cell line (L428), the SU-DHL6 diffuse large B-cell lymphoma (DLBCL) cell line and thirteen EBV-transformed LCLs (NOR-, RIC-, STA-, FOL-, LOV-, RIV-, WOL-, FW-, VS-, MA-, SC-, DS-, and DW-LCL) were maintained in RPMI-1640 supplemented with 10% FBS (Cellgro Media Tech, Manassas, VA), 2 mM glutamine, 50 u/mL penicillin and 50 u/mL streptomycin. The 293T cell line was purchased from ATCC and maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS.
Analysis of Gal1 transcript abundance by gene expression profiling. Gene expression profiling data were obtained for two previously described data sets. 13 For luciferase assays, the 293T cell line was grown to 60-80% confluency on 6 wellplates and co-transfected with 150 ng/well of the previously described LGALS1 promoter pGL3 construct, 4 100 ng/well of the control reporter plasmid, pRL-PGK, and 150 ng/well of LMP1-FLAG and/or LMP2A-FLAG or 150-300 ng of empty pFLAG-CMV2 vector (total amount of 550 ng of combined plasmids per well). Transfection was performed using Densitometric analysis of bands was performed using ImageJ software (National Institutes of Health, Bethesda, MD). Additional assays of Gal1 promoter and enhancerdriven luciferase activity in EBV-transformed LCLs were performed as previously described. 4 In brief, NOR cells were cotransfected with 300 ng of the pGL3-Gal1-promoter constructs (without or with wild-type or mutant AP-1 dependent enhancer) and 100 ng of the control reporter plasmid, pRL-TK, and evaluated for relative luciferase activity as described. 4 Endogenous levels of total and active cJun and JunB were evaluated by immunoblotting. Anti-Gal1 mAb-mediated neutralization of Gal1-induced T-cell apoptosis. Normal T cells were purified and activated with a combination of αCD3 (0.1 µg/mL) and αCD28 (0.5 µg/mL) as previously described. 4 Ten μM recombinant human Gal1 (rGal1) was preincubated with 5 μM αGal1 mAb 8F4F8G7 or isotype control IgG2bλ (Rockland Immunochemicals Inc., Boyertown, PA) or medium alone at 37°C for 30 min. Thereafter, rGal1 +/-antibody was added to in vitro αCD3 and αCD28 activated T cells. After 16 h treatment, cells were harvested for apoptosis analysis using Annexin V-FITC and PI (BD Biosciences, San Jose, CA) flow cytometry as previously described. 
Results

Gal1 expression in EBV-transformed lymphoblastoid cell lines and primary posttransplant lymphoproliferative disorders (PTLDs). We first characterized Gal1
transcript abundance in EBV-transformed LCLs, cell lines from additional B-cell malignancies including classical Hodgkin lymphoma (cHL), and additional normal B cells using publicly available gene expression profiles. 20 Gal1 transcripts were similarly abundant in EBV-transformed LCLs and cHL cell lines (Supplemental Figure 1) . For these reasons, we further assessed Gal1 protein expression in a series of EBVtransformed LCLs using a recently developed αGal1 mAb, 8F4F8G7 (Supplemental Figure 2 and data not shown). All of the examined EBV-transformed LCLs expressed the ≈ 14kD Gal1 protein as did the cHL cell line ( Figure 1A ).
We next evaluated a series of primary EBV + PTLDs for Gal1 expression by immunohistochemical staining; 76% (13/17) of primary EBV + PTLDs were Gal1 + whereas only 4% (3/64) of primary DLBCLs expressed Gal1 ( Figure 1B and Table 1 ).
Similar results were obtained with the Gal1 mAb (8F4F8G7, Figure 1B and Table 1 ) and the previously described Gal1 polyclonal antibody (Supplemental Figure 3,  4 ) .
AP-1 dependent Gal1 expression in EBV-transformed LCLs and primary PTLDs.
We previously found that Gal1 expression in cHL was mediated, in part, by an AP-1 dependent Gal1 enhancer. 4 Because LMP1 and LMP2A both activate the AP-1 pathway and promote the formation of cJun/JunB heterodimers, [27] [28] [29] we assessed the role of the AP-1 dependent Gal1 enhancer in EBV-transformed LCLs. We first assessed the abundance and phosphorylation of the AP-1 signaling components, cJun and JunB, in representative EBV-transformed LCLs (NOR and RIC) by immunoblotting. Total and phosphorylated cJun and JunB were readily detectable in the LCLs and the control cHL cell line (L428) (Figure 2A ). Thereafter, we confirmed that cJun and JunB both bound to the previously described Gal1 enhancer 4 in LCLs by ChiP-PCR ( Figure 2B ).
Densitometric analysis of ChIP-PCRs revealed that JunB bound Gal1 enhancer regions at higher levels than cJun ( Figure 2C ), highlighting the likely role of JunB as a regulator of Gal1 expression. In addition, we assessed LCL luciferase activity driven by the Gal1 promoter alone or in tandem with the Gal1 enhancer element with an intact or mutated AP-1 binding site. 4 Although the Gal1 promoter alone was active in the NOR LCL cell Figure 2E, panels b, d, f) . This was in contrast to primary DLBCLs, which our group previously found to be largely negative for phospho-cJun staining 22 . Immunohistochemical analysis of JunB revealed uniformly strong nuclear staining in all PTLD tumors (15/15) ( Figure 2E, panels a, c, e) . Together, these data highlight the role of the AP-1 dependent Gal1 enhancer and respective AP-1 components in Gal1 expression in EBV-transformed LCLs and primary PTLDs.
Gal1 promoter activity in EBV-transformed LCLs is driven by LMP1 and LMP2A.
Given the pivotal role of the EBV latency genes, LMP1 and LMP2A, in EBV-induced Bcell transformation, 11, 30, 31 we asked whether LMP1 and LMP2A modulated Gal1 expression. First, we compared Gal1 transcript abundance in control and LMP1-transduced normal CD10 + human GCB cells using publicly available gene expression profiles 13 and found that Gal1 was ≈ 2-fold more abundant in LMP1-transduced GCB cells (Supplemental Figure 4) . Thereafter, we evaluated the respective roles of LMP1
and LMP2A in Gal1 transcriptional activation by co-transfecting LMP1 and/or LMP2A and a Gal1 promoter-driven luciferase reporter into 293T cells and evaluating Gal1-driven luciferase activity. Expression of LMP1 or LMP2A increased Gal1-driven luciferase activity by ≈ 4.5-and 2.5-fold, respectively, and co-expression of both LMP proteins was additive ( Figure 3A) . In complementary studies, siRNA-mediated LMP2A depletion markedly decreased Gal1 expression in an EBV-transformed LCL (NOR) ( Figure 3B ). Taken together, the data directly implicate the EBV proteins, LMP1 and LMP2A, in the transcriptional activation of Gal1.
We next performed an analysis of the regulatory motifs and modules within the Gal1 promoter region and identified a candidate NFκB binding site, two putative STAT binding sites and a NFAT/NFY module (Supplemental Figure 5) ; each represents a binding site for transcription factors that can be activated by LMP1/LMP2A directly (NFκB and STAT) or indirectly (NFAT and NFY activation by PI3K/Akt). Having identified these putative
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From transcription factor binding sites in the Gal1 promoter, we utilized inhibitors of NFκB, JAK/STAT and PI3K/Akt activity to assess the potential roles of these signaling pathways in Gal1 induction. Overexpression of an IκB super-repressor construct in an LCL cell line (NOR) decreased the abundance of known NFκB target genes, but had no effect on Gal1 expression (data not shown). Similarly, exposure of LCLs to a pan-JAK inhibitor decreased abundance of phospho-STAT5, but had no effect on Gal1 expression (data not shown). In contrast, treatment of two EBV-transformed LCLs (NOR and RIC) with a chemical inhibitor of PI3K activity (Ly294002) reduced Gal1 expression ( Figure   3C ). Taken together, these data suggest that PI3K, but not NFκB or JAK/STAT, signaling augments Gal1 expression in EBV-transformed LCLs.
Gal1 neutralizing mAb inhibits rGal1-mediated killing of EBV-specific cytotoxic T cells.
Given the demonstrated role of Gal1 in tumor immune escape, 3, 4 neutralization of Gal1 activity may represent a novel therapeutic strategy for Gal1-expressing tumors. For this reason, we developed high-titer neutralizing monoclonal antibodies (mAb) directed against the Gal1 protein. We first screened these Gal1 mAbs for their capacity to inhibit recombinant-Gal1 (rGal1)-mediated apoptosis of in vitro activated T cells. 4 The Gal1 mAb, 8F4F8G7, almost completely inhibited rGal1-induced apoptosis of normal αCD3/αCD28-activated T cells whereas an isotype-matched control antibody had no effect ( Figure 4A-B) .
For these reasons, we next assessed the effects of 8F4F8G7 on rGal1-mediated apoptosis of EBV-specific CD8 + T cells. In these assays, rGal1 (1.25, 2.5 or 5 μM) was pre-incubated with the neutralizing Gal1 monoclonal antibody (8F4F8G7) or an isotypematched control (IgG2bλ). Thereafter, EBV-specific, largely CD8 + , T cells were cultured alone, with rGal1 alone, or with rGal1 pre-incubated with 8F4F8G7 or the isotype control; following 4 h treatment, the percent of viable CD8 + (7AAD negative) cells was determined ( Figure 5 ). At all doses, rGal1 alone induced massive apoptosis of EBV- 
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additional independent donors (Supplemental Figure 5A-B) . Taken together, these data demonstrate that EBV-specific CD8 + T cells are exquisitely sensitive to rGal1-mediated apoptosis and that the neutralizing αGal1 mAb, 8F4F8G7, abrogates rGal1-induced apoptosis of EBV-specific T cells. Therefore, antibody (8F4F8G7)-mediated blockade of secreted Gal1 may represent a novel immunotherapeutic strategy in EBV-associated PTLD and other Gal1 + tumors.
For
Discussion
The link between T-cell dysfunction and outgrowth of Epstein-Barr Virus (EBV)-infected B cells is well established. 32 Herein, we have shown that the immunomodulatory carbohydrate-binding lectin, Gal1, is selectively expressed in EBV-transformed LCLs and primary PTLDs and provided evidence that Gal1 expression is enhanced by EBVencoded latent membrane proteins and signaling via AP-1 and PI3K. Furthermore, we have developed a high-titer neutralizing Gal1 mAb that abrogates Gal1-induced apoptosis of EBV-specific cytotoxic T cells. These findings define EBV-associated Gal1 expression as a novel mechanism of viral immune evasion and highlight the potential utility of Gal1-neutralizing therapy for PTLD and other Gal1-expressing tumors.
In light of the known capacity of LMP1 and LMP2A to activate AP-1 signaling, and our previous description of the AP-1-responsiveness of Gal1 in cHL, 4, 22 We also observed that luciferase constructs containing only the Gal1 promoter were active in an EBV-transformed cell line. As a consequence, we evaluated the capacity of LMP1/LMP2A signaling to activate the Gal1 promoter by co-expressing LMP1 and/or LMP2A with the Gal1 promoter-driven luciferase construct in an EBV-negative cell line.
LMP1 and, to a lesser extent, LMP2A increased Gal1 promoter activity and the coexpression of both antigens was additive. In order to characterize the mechanism by which LMP1/LMP2A activated Gal1 promoter activity, we performed a detailed analysis of regulatory elements within the Gal1 promoter sequence and found conserved NFκB,
NFAT and NFY sites. LMP1 and LMP2A have the potential to induce signaling through pathways that activate these transcription factors-LMP1 to activate NFκB and 41 PTLD is an excellent disease setting for evaluating the utility of a Gal1-neutralizing antibody because LMP-specific cytotoxic Tcells are highly sensitive to Gal1-induced apoptosis ( Figure 5 , 36 ).
We therefore developed Gal1 specific mAbs and screened for their ability to neutralize rGal1-induced apoptosis of EBV-specific cytotoxic T-cells. Gal1 mAbs that exhibited high affinity and specificity for recombinant and endogenous Gal1 were first evaluated for their capacity to abrogate rGal1-mediated apoptosis of activated T-cells in vitro. The most effective neutralizing Gal1 mAb, 8F4F8G7, was then assayed against highly Gal1-susceptible EBV-specific CTLs. Incubation of EBV-specific donor CTLs with 8F4F8G7 dramatically reduced rGal1-mediated apoptosis compared to the isotype control antibody highlighting the potential utility of this mAb in Gal1-neutralizing therapy.
In summary, we have shown that EBV-transformed LCLs and primary PTLDs exhibit strong expression of Gal1 that is promoted by the LMP1 and LMP2A viral antigens through PI3K/Akt and AP-1 signaling. In addition, we have developed a Gal1-neutralizing mAb that protects against rGal1-induced apoptosis of EBV-specific cytotoxic T-cells.
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